Fresenius SE & Co. KGaA

Company Overview

Fresenius is a global healthcare company providing essential products and services for leading therapies for critically and chronically ill patients. The company operates through business segments: Fresenius Kabi, Fresenius Helios, Fresenius Vamed, and Fresenius Medical Care. However, Fresenius Medical Care was deconsolidated as of November 2023.

The company caters to the infusion pump and device market through the Fresenius Kabi business. Fresenius Kabi specializes in products for treating and caring for critically and chronically ill patients. Biopharmaceuticals, clinical nutrition, MedTech products, generic IV drugs, and IV fluids are included in its portfolio. The company has over one million infusion pumps globally, aiding optimize patient care.

Fresenius operates in more than 60 countries through its subsidiaries, with primary markets in Europe and North America. The company maintains an international distribution network and has over 50 production sites.

Financial Highlights (FY 2023)

Company's Business Segments

• Fresenius Kabi : This segment includes biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs (generic IV drugs), and IV fluids.
• Fresenius Helios : It is Europe’s leading private healthcare service provider, and its portfolio includes Helios Germany, Helios Spain, and Eugin Group (which was sold on January 31, 2024).
• Fresenius Vamed : This segment manages projects and provides services for hospitals and other healthcare facilities internationally. The services cover the entire value chain, from development, planning, and turnkey construction to maintenance, technical management, total operational management, and higher services.